Clinical trial for Neoplasms
Official title A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT07277270
What this study is testing
What is GSK5764227?
An investigational medicine being studied for the treatment of neoplasms.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see how safe the drug is, how the body handles it, whether it triggers immune reactions, and if it can shrink or control tumors.
- Who it's for
- Adults with advanced solid tumors who have not responded to other treatments.
- What's involved
- Participants will receive the drug along with their usual cancer therapy, attend clinic visits, and undergo blood tests and scans to monitor safety and tumor response.
- Time commitment
- The trial lasts several months, with regular clinic visits and tests scheduled throughout the study period.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose.
- Has adequate organ function.
- Has histologically confirmed unresectable adenocarcinoma or unresectable metastatic adenocarcinoma of the colon or rectum. (Cohort A)
- Histologically or cytologically confirmed adenocarcinoma of the prostate (Cohort B)
You likely can't join if
- Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or...
- Has had any major surgery within 28 days prior to first dose.
- Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.
- Has serious infection within 4 weeks prior to the first dose,
- Has untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed
- Any evidence of current interstitial lung disease (ILD) or pneumonitis OR a prior history of ILD requiring high-dose glucocorticoids or...
See the full eligibility criteria
- Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose.
- Has adequate organ function.
- Has histologically confirmed unresectable adenocarcinoma or unresectable metastatic adenocarcinoma of the colon or rectum. (Cohort A)
- Histologically or cytologically confirmed adenocarcinoma of the prostate (Cohort B)
- Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas [e.g., breast...
- Has had any major surgery within 28 days prior to first dose.
- Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.
- Has serious infection within 4 weeks prior to the first dose,
- Has untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed
- Any evidence of current interstitial lung disease (ILD) or pneumonitis OR a prior history of ILD requiring high-dose glucocorticoids or non-infectious pneumonitis requiring high-dose glucocorticoids.
- Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening.
- Has received immunosuppressive agents within 30 days prior to first dose of study intervention (or requires long-term [30 days or longer]).
The study team makes the final eligibility decision.
Where it is enrolling
- Reunion, Florida, United States
- New Hyde Park, New York, United States
- Philadelphia, Pennsylvania, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
- Douglas, Queensland, Australia
- Tugun, Queensland, Australia
- Geelong, Victoria, Australia
- Bendigo, Australia
- Ottawa, Ontario, Canada
- Toronto, Ontario, Canada
- Seoul, South Korea
- Barcelona, Spain
- Madrid, Spain
- Málaga, Spain
- Leicester, United Kingdom
- London, United Kingdom
- Sutton, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Reunion, Florida, United States; New Hyde Park, New York, United States; Philadelphia, Pennsylvania, United States; Nashville, Tennessee, United States; Dallas, Texas, United States; Douglas, Queensland, Australia and 12 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.